Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Analysts at Wedbush issued their FY2022 EPS estimates for shares of Intercept Pharmaceuticals in a research report issued on Thursday. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings of $21.10 per share for the year. Wedbush currently has a “Buy” rating and a $253.00 target price on the stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. During the same period in the prior year, the company posted ($3.59) EPS. The business’s revenue for the quarter was up 697.9% on a year-over-year basis.
Intercept Pharmaceuticals (ICPT) opened at $64.92 on Monday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12 month low of $51.53 and a 12 month high of $135.59.
A number of large investors have recently added to or reduced their stakes in ICPT. Senvest Management LLC purchased a new position in Intercept Pharmaceuticals in the 3rd quarter valued at about $33,883,000. Peregrine Capital Management LLC purchased a new position in Intercept Pharmaceuticals in the 4th quarter valued at about $7,055,000. Balyasny Asset Management LLC purchased a new position in Intercept Pharmaceuticals in the 2nd quarter valued at about $13,766,000. Vanguard Group Inc. lifted its holdings in Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares in the last quarter. Finally, Asymmetry Capital Management L.P. purchased a new position in Intercept Pharmaceuticals in the 2nd quarter valued at about $3,580,000. Institutional investors own 73.74% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Wedbush Weighs in on Intercept Pharmaceuticals Inc’s FY2022 Earnings (ICPT)” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/29/wedbush-weighs-in-on-intercept-pharmaceuticals-incs-fy2022-earnings-icpt.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.